about
Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowthActivity of sirolimus in patients with myelodysplastic syndrome--results of a pilot study.Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females.Cholesterol: its regulation and role in central nervous system disorders.The use of error and uncertainty methods in the medical laboratory.cAMP-induced expression of ABCA1 is associated with MAP-kinase-pathway activation.Endocytosis and intracellular trafficking of fatty acid esters of phenylaminopropanediol, the putative etiologic agents of the toxic oil syndrome (TOS).Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: isoform-specific effects on neurodegeneration.Point-of-care testing in hospitals and primary care: Unsatisfactory quality.Quintessence unjustified.Multicenter analytical evaluation of the automated electrochemiluminescence immunoassay for cyclosporine.Prevention of CA-MRSA.A new concept for acne therapy: a pilot study with zileuton, an oral 5-lipoxygenase inhibitor.Chylomicron remnant concentrations in patients with coronary artery disease.Human serum gangliosides in hypercholesterolemia, before and after extracorporeal elimination of LDL.Are regulation-driven performance criteria still acceptable? - The German point of view.Opinion: redefining the role of the physician in laboratory medicine in the context of emerging technologies, personalised medicine and patient autonomy ('4P medicine').Multi-center analytical evaluation of a novel automated tacrolimus immunoassay.Hemostatic factors in hypertriglyceridemic men: effects of a fatty meal before and after triglyceride-lowering treatment with etofibrate.Clearance of postprandial lipoproteins in normolipemics: role of the apolipoprotein E phenotype.Effects of VLDL, chylomicrons, and chylomicron remnants on platelet aggregability.Long-term medical data storage: challenges with test results obtained by direct-to-consumer testingDirect-to-Consumer TestingDer zlog-Wert als Basis für die Standardisierung von LaborwertenFestlegung der zulässigen Messunsicherheit quantitativer Messgrößen in der LaboratoriumsmedizinChancen und Risiken von e-Health in der LabormedizinCorrigendum zu: Chancen und Risiken von e-Health in der LabormedizinRecommendations for the frequency of ordering laboratory testingEmpfehlungen zur Häufigkeit der Anforderung von LaboruntersuchungenUmfrage zur Laborberatung in DeutschlandComparability and Imprecision of 8 Frequently Used Commercially Available Immunoassays for Therapeutic Drug MonitoringKey figures and benchmarking in the hospital laboratory1)Pro und Contra der Thrombophiliediagnostik/Pros and cons of thrombophilia testingPros and cons of thrombophilia testing1)Kennzahlen und Benchmarking im Krankenhauslabor/Key figures and benchmarking in the hospital laboratoryAntibiotika am KrankenbettPraktische Umsetzung des Gendiagnostikgesetzes (GenDG) in der Laboratoriumsmedizin, dem humangenetischen Laboratorium und der humangenetischen Beratung/Practical Implications of the German Genetic Diagnostics Act (GenDG) for Laboratory Medicine, theQuality in Laboratory Hemostasis and ThrombosisCSF interleukin 6 – a useful biomarker of meningitis in adults?/Liquor Interleukin 6 – ein sinnvoller Biomarker für die Meningitis beim ErwachsenenThrombozytenhemmende Therapie in der Kardiologie: aktuelle Entwicklungen bei Therapie und Monitoring / Antiplatelet drugs in cardiology: current trends in therapy and monitoring
P50
Q28771743-78066E0F-5C66-42AA-B85A-DD526B1B9B96Q33365126-F8179E40-C5EE-4FF5-BA9A-7A964493A143Q33563135-9CD4068C-1060-4898-A995-75F8EC75B09CQ36355194-ABB4F71E-9410-40F6-BF83-0F71ACC45A7CQ38630512-B7A6641D-DB22-45E9-B82E-FAD663082699Q40080479-134E1E39-9E8B-4F09-8E5D-10385039306AQ40340963-7D87335F-BB12-4ED9-97CA-64FE47233A7DQ41671941-4914616C-BF42-4424-9250-5C0510E76A7DQ42682174-89A7DC1F-D14C-425A-B3B6-41BDB33F9EE5Q42842943-8EB744AB-3382-4EE1-A531-EB48848E2D1CQ42973580-6255B5AB-D318-49FA-AB90-B68C45B8D8D4Q43163357-74DACBEC-8952-4B9B-AFAF-4F348EC6F29CQ44447053-68D0CEB0-05EE-435F-B4D4-851BD5A5A996Q44481620-A8843469-57A6-4A16-A73C-30026EF3296EQ44584370-5FC969EF-4520-403D-ADCD-B2FD8A14A07FQ48205307-4BF81F7C-6845-47A8-9501-C3FFFB256AE9Q48354325-205293CD-AFBE-4A82-9AA7-35E47603B4DBQ49076460-67CA84A8-6543-42CC-A676-2B268169F65FQ51562558-446AB787-5BCE-41A0-8F3B-9A0659ADF5B4Q51579468-F272796F-D4EA-4A7A-8698-34C22638AC0EQ54270411-5D7FBCF9-303E-41F6-8438-586970972273Q62662148-164971D1-290C-4093-B8A4-4AE050107C33Q62662149-B089524F-1B00-4146-BB5A-095D53660B4CQ62662151-998EC94A-E867-4B9D-A739-00170F9D4481Q62662152-73429919-C535-49AF-A382-2845C2E3C073Q62662155-16965B1B-AD87-4FD9-9017-4719CA85246EQ62662157-95A64837-111D-4D00-9310-C94E31093F1DQ62662158-E9E00092-8EF3-41F1-8316-28D7BA19B425Q62662159-0119E08C-D927-473E-A7B4-A22ACB7A7719Q62662161-EFB6C930-0E15-4195-A79A-28E0819162E1Q62662162-B9D9DC01-6D45-448C-A7B5-2E039AFF3347Q62662164-7675BCC6-CAC8-483A-81A7-31DE311CCC30Q62662165-18377B6D-E83F-4AF9-86A4-6E696BED98EAQ62662167-55C75BC7-C52C-4B60-9DEE-C1131131DAB5Q62662169-FA8F43D9-C12A-44DD-92AF-5ADBA2A74E01Q62662171-4CA8ED7E-BC97-4247-AD81-5A415D29A659Q62662173-45A2BE15-A10F-4B32-B5B3-D210E83C19D6Q62662174-6019079D-0E4D-4E83-AFC4-73B3A2130BEEQ62662176-BC8D6EBB-D2EB-4B7A-8181-303B405A85B6Q62662181-51480341-0AF7-4974-8206-371D9A4256D7
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Matthias Orth
@ast
Matthias Orth
@en
Matthias Orth
@es
Matthias Orth
@nl
Matthias Orth
@sl
type
label
Matthias Orth
@ast
Matthias Orth
@en
Matthias Orth
@es
Matthias Orth
@nl
Matthias Orth
@sl
prefLabel
Matthias Orth
@ast
Matthias Orth
@en
Matthias Orth
@es
Matthias Orth
@nl
Matthias Orth
@sl
P214
P106
P1153
7006240112
P21
P214
P31
P496
0000-0003-2881-8384
P735
P7859
viaf-60142864